Principal Securities Inc. Lowers Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Principal Securities Inc. lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 26.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 327 shares of the medical equipment provider’s stock after selling 119 shares during the period. Principal Securities Inc.’s holdings in Lantheus were worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of LNTH. Groupama Asset Managment bought a new position in Lantheus in the 3rd quarter worth $439,000. Swedbank AB lifted its stake in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after purchasing an additional 385,000 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock valued at $393,844,000 after buying an additional 257,022 shares in the last quarter. Massachusetts Financial Services Co. MA bought a new stake in Lantheus in the third quarter worth $25,955,000. Finally, Point72 DIFC Ltd bought a new position in shares of Lantheus in the 3rd quarter valued at about $23,001,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $93.82 on Friday. The company has a 50-day simple moving average of $89.80 and a 200-day simple moving average of $96.75. Lantheus Holdings, Inc. has a one year low of $56.44 and a one year high of $126.89. The stock has a market capitalization of $6.52 billion, a price-to-earnings ratio of 15.61 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. As a group, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages have issued reports on LNTH. Truist Financial boosted their target price on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $132.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.